论文部分内容阅读
目的 探讨钙拮抗剂与腹腔内化疗联合应用对荷肝癌大鼠的作用及钙拮抗剂与细胞毒药物的相互作用。方法 采用肝被膜下植入法建立肝癌动物模型,将荷瘤大鼠分成四组:A组(对照组),腹腔内注射6ml生理盐水,每天1次,连续3天;B组(单纯化疗组),腹腔内注射5-Fu75mg/kg,容量6ml,每天1次,连续3天;C组(联合用药组),腹腔内注射5-Fu 75mg/kg和维拉帕米25ml/kg,总容量6ml,每天1次,连续3天;D组(单纯维拉帕米组),腹腔内注射维拉帕米25mg/kg,总容量6ml,每天1次,连续3天。结果 联合给药组的肿瘤体积比单纯化疗组明显缩小,其抑瘤率显著高于单纯化疗组。结论 钙拮抗剂维拉帕米能明显提高5-Fu腹腔内化疗对肝癌的治疗作用。
Objective To investigate the effect of calcium antagonist combined with intraperitoneal chemotherapy on hepatocarcinoma-bearing rats and the interaction between calcium antagonists and cytotoxic drugs. Methods Liver cancer was established by subconjunctival implanted method. The tumor-bearing rats were divided into four groups: group A (control group), intraperitoneal injection of 6ml normal saline once daily for 3 days; group B ), Intraperitoneal injection of 5-Fu75mg / kg, volume 6ml, once a day for 3 days; C group (combination group), intraperitoneal injection of 5-Fu 75mg / kg and verapamil 25ml / kg, total capacity 6ml, once a day for 3 consecutive days; group D (verapamil group), intraperitoneal injection of verapamil 25mg / kg, a total capacity of 6ml once daily for 3 days. Results The tumor volume of the combined treatment group was significantly smaller than that of the chemotherapy alone group, and its tumor inhibition rate was significantly higher than that of the chemotherapy alone group. Conclusion The verapamil, a calcium antagonist, can significantly improve the therapeutic effect of 5-Fu intraperitoneal chemotherapy on hepatocellular carcinoma.